Welcome to our dedicated page for DENTSPLY SIRONA news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on DENTSPLY SIRONA stock.
DENTSPLY SIRONA Inc. (symbol: XRAY) stands as the world’s largest manufacturer of professional dental products and technologies. As a global total solutions provider, Dentsply Sirona empowers dental professionals to offer better, safer, and faster dental care. The company’s extensive portfolio includes leading positions in consumables, equipment, technology, and specialty products. Dentsply Sirona is committed to innovation and quality, reflected in its comprehensive end-to-end solutions offering, which spans well-known and established brands in the industry.
Dentsply Sirona emerged from a merger between Dentsply International and Sirona Dental Systems in 2016. Today, the company manufactures and markets a complete range of dental and oral health products, including dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation.
Recently, Dentsply Sirona has announced enhancements to its DS Core platform, a cloud-based solution supporting dental professionals throughout the entire treatment continuum. The platform now boasts improved patient communication tools, a unified ordering system, and support for additional data formats, making it easier for dental practices to collaborate with labs and service providers.
Financially, Dentsply Sirona maintains a robust presence in the dental industry, with significant revenue generated through third-party distributors and direct sales to labs, offices, and consumers. The company’s ongoing commitment to innovation is further demonstrated by its DS World Las Vegas event, an annual gathering that provides dental professionals with market-leading education, networking opportunities, and exposure to the latest dental technologies.
With its headquarters in Charlotte, North Carolina, Dentsply Sirona continues to shape the future of dentistry, striving to enhance patient care and advance dental practices through its unwavering dedication to quality and innovation. For more information on Dentsply Sirona and its products, visit the official website.
Dentsply Sirona has partnered with Smile Train and FDI World Dental Federation to launch the first global protocols for digital cleft treatment. This initiative aims to enhance the quality and accessibility of cleft care worldwide. The protocols, developed through extensive research and expert consensus, will guide dental professionals at every treatment stage, covering areas such as presurgical orthopedics and oral rehabilitation. An interactive tool has been created to facilitate the application of this information, ensuring a user-friendly experience for practitioners. Dentsply Sirona has been instrumental in funding cleft surgeries and is committed to improving care for underserved communities globally, aligning with its sustainability strategy.
Dentsply Sirona, the largest manufacturer of professional dental products, announced an investor conference call on May 3, 2023, at 8:30 am ET. This call will discuss the company’s first quarter financial results. The live webcast can be accessed via the Investors section of their website. Registrants can secure their participation through this link, and a replay will be made available afterward.
Dentsply Sirona has a long-standing history of innovation in the dental industry and continues to provide high-quality solutions for patient care. Their products are marketed under various world-class brands, enhancing dental and oral health worldwide.
Dentsply Sirona (Nasdaq: XRAY) announced a $150 million accelerated share repurchase (ASR) agreement with Goldman Sachs, aimed at enhancing shareholder value. Under this agreement, the company will initially acquire around 3.1 million shares. The final share count will be determined based on the stock's average price during the ASR's valuation period, with potential adjustments affecting total expenditure. The completion of this ASR is expected by the end of Q2 2023, reflecting Dentsply Sirona's commitment to returning capital to shareholders and optimizing its capital structure.
DENTSPLY SIRONA reported a challenging FY22 with net sales decreasing by 7.3% to $3,922 million, compared to $4,231 million in FY21. The company experienced a net loss of $950 million or ($4.41) per share, significantly down from a net income of $411 million in FY21. Q4 showed a 10.9% drop in net sales to $983 million, with adjusted EPS falling 44.4% to $0.46. For FY23, the outlook suggests net sales between $3.85 billion and $3.95 billion, with adjusted EPS anticipated in the range of $1.80 to $2.00.